hero section gradient
11 handpicked stocks

Made in China

This carefully curated collection features the most influential Chinese companies trading on US exchanges. Handpicked by our analysts, these stocks represent powerhouses in tech, e-commerce, and electric vehicles from the world's second-largest economy.

Author avatar

Han Tan | Market Analyst

Published on May 23

Your Basket's Financial Footprint

Summary and investor takeaways for the 'Made in China' basket based on provided market capitalisation breakdown.

Key Takeaways for Investors:
  • Large-cap dominance tends to mean lower volatility and closer tracking of the broader market, implying steadier performance.
  • Consider this basket as a core holding for diversified portfolios rather than a short-term speculative position.
  • Expect steady long-term appreciation rather than explosive short-term gains; growth is more likely gradual.
Total Market Cap
  • BABA: $397.68B

  • NIO: $16.63B

  • BIDU: $40.96B

  • Other

About This Group of Stocks

1

Our Expert Thinking

China's $17.5 trillion economy represents enormous growth potential for investors. These companies are leaders in technological innovation, e-commerce, and electric vehicles, offering exposure to China's expanding consumer base and digital transformation.

2

What You Need to Know

Chinese stocks can offer attractive valuations compared to Western counterparts and provide excellent portfolio diversification. Government policies and initiatives often create tailwinds for certain sectors, though regulatory environments can shift.

3

Why These Stocks

Each company in this collection is an established industry leader with significant market presence. Our analysts selected these stocks based on their growth potential, innovative capabilities, market position, and ability to capitalize on China's expanding economy.

Why You'll Want to Watch These Stocks

🚀

Innovation Powerhouses

These companies are at the forefront of technological breakthroughs in e-commerce, electric vehicles, and digital platforms. Many are innovating faster than their Western counterparts.

💰

Value Opportunity

Chinese stocks often trade at lower valuations compared to similar US companies despite comparable growth profiles. This potential undervaluation could mean significant upside for investors.

🌏

Tap Into China's Growth

With a massive consumer market of 1.4 billion people and a growing middle class, these companies are positioned to benefit from China's continued economic expansion and increasing consumer spending power.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

🚀

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Employment Resilience: Could Stocks Outperform?

Employment Resilience: Could Stocks Outperform?

Recent economic data reveals unexpected resilience in the U.S. labor market, with unemployment holding steady and jobless claims declining. This stability creates a favorable environment for companies reliant on consumer spending and those providing essential employment services.

EV Supply Chain Risks as Market Shifts to Mass Production

EV Supply Chain Risks as Market Shifts to Mass Production

BYD has officially surpassed Tesla as the world's top seller of battery electric vehicles, signaling a major shift in the global auto industry. This change highlights a growing opportunity for companies that supply the components and materials essential for producing affordable, mass-market EVs.

Drug Pricing Power | Major Pharma Stocks 2025

Drug Pricing Power | Major Pharma Stocks 2025

Following plans by major drugmakers to raise prices on hundreds of medications, the pharmaceutical industry is showcasing its significant pricing power. This development highlights an investment opportunity centered on established pharmaceutical companies capable of translating market dominance into revenue growth.

Frequently Asked Questions